MG132: Selectivity & Specificity
MG132 is a potent inhibitor of Mycobacterium tuberculosis proteasome (27.97 μM), Proteasome (10 µg/kg/day), RET, Progerin, Prelamin A, NPC1, GM1, Cholesterol, Oocyte meiotic resumption (90%), F-actin-rich TZPs, HAS2, TNFAIP6, Progesterone synthesis, Proteasome β5, CTSA, TPP2, CAPN1, MHV, SARS-CoV, IL6, ICAM1, CXCL10, CCL2, MIF, CCL5, DUSP1, VNN1, CASP3, SRSF1, NFE2L2 (10 µg/kg/day), NFKB, NFKBIA, Oocyte-cumulus ECM formation, HA synthesis, HA-IαI covalent binding, F-actin-rich TZPs degradation, TGFB, MAPK, SMAD7, SOD, GPX (10 µg/kg/day), SERPINE1, PI3K, AKT, H2O2-mediated oxidative stress (0.5 µM), Cardiac hypertrophy (0.1 mg/kg/day), Endothelial dysfunction, SOD1 (10 µg/kg/day), Heme-mediated oxidative injury (1 µM), HMOX1, Cisplatin-induced nephrotoxicity, Renal fibrosis (low doses), CAT (10 µg/kg/day), NOX, CNBP. MG132 exhibits the greatest inhibitory potency toward H2O2-mediated oxidative stress (IC50 = 500 nM).